ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk

Hongmei Zhang,1 Li Qin,2 Chang-Sheng Sheng,3 Yixin Niu,1 Hongxia Gu,2 Shuai Lu,2 Zhen Yang,1 Jingyan Tian,4 Qing Su1

ABSTRACT

Objective To investigate the association between hemoglobin A1c (HbA1c) 7.0%–8.0% and cardiovascular disease (CVD) risk among Chinese patients with type 2 diabetes mellitus (T2DM) with different baseline 10-year atherosclerotic CVD (ASCVD) risk stratification.

Research design and methods A prospective population-based cohort of 10 060 adults aged 40–70 years in Chongming District of Shanghai was established in 2011. These participants were followed up for 3.25 years and CVD information was recorded. We investigated this association between HbA1c categories and incident CVD stratified by the 10-year ASCVD risk using multiple Cox regression analysis among 1880 patients with T2DM without CVD history. CVD events were defined as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.

Results The corresponding incidence of CVD per 1000 person-years for the HbA1c≤6.5%, 6.6%–6.9%, 7.0%–8.0% and >8.0% groups were 12.5, 21.8, 22.9 and 28.9, respectively. The HbA1c>8.0% group was significantly associated with a higher CVD risk in patients with T2DM. The HbA1c 7.0%–8.0% group was significantly associated with a higher CVD risk in patients with T2DM with moderate baseline ASCVD risk (HR 2.48; 95% CI 1.15 to 5.32).

Conclusion HbA1c of 7.0%–8.0% may result in a significantly higher CVD risk among patients with T2DM with moderate baseline ASCVD risk, which support the use of HbA1c combined with baseline ASCVD risk assessment to determine future glucose-lowering treatment decisions among patients with T2DM with basic to moderate risk.

INTRODUCTION

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality for individuals with diabetes and the greatest contributor to direct and indirect costs of diabetes.1 As a marker to identify the average plasma glucose concentration during preceding 10–12 weeks, hemoglobin A1c (HbA1c) was used to monitor the control of blood glucose in patients with diabetes.2 Despite abundant observational studies and clinical trials having demonstrated an association between HbA1c and cardiovascular disease (CVD) events, there is conflicting evidence regarding appropriate HbA1c targets for reducing CVD events in patients with type 2 diabetes mellitus (T2DM).

Since the American College of Physicians published a guidance statement on HbA1c targets for glycemic control with pharmacological therapy for non-pregnant adults with type 2 diabetes mellitus in March 2018 which recommended that clinicians should aim to achieve an HbA1c level between 7.0% and 8.0% in most patients with T2DM, significant controversy has arose around the applicability of the guideline to patients with T2DM with HbA1c 7.0%–8.0%.3–5 Experts from American Diabetes Association believed the recommendation is at odds with those of

Significance of this study

What is already known about this subject?

► Hemoglobin A1c (HbA1c) >8.0% group was significantly associated with a higher cardiovascular disease (CVD) risk in patients with type 2 diabetes mellitus (T2DM).

What are the new findings?

► HbA1c of 7.0%–8.0% may result in a significantly higher CVD risk among patients with T2DM with moderate baseline atherosclerotic CVD (ASCVD) risk.

How might these results change the focus of research or clinical practice?

► Using HbA1c combined with baseline ASCVD risk assessment to determine future glucose-lowering treatment decisions among patients with T2DM with basic to moderate risk.
other professional organization and suggested that a reasonable HbA1c goal for many non-pregnant adults is <7%.

ASCVD risk score is a comprehensive index for evaluation of the risk of future CVD events. Cardiovascular risk stratification is widely used for evaluating the risk of hypertension-related CVD events and blood lipid management. However, there was no study to investigate the effect of ASCVD risk stratification on management of hyperglycemia in patients with T2DM, whether in observational studies or randomized clinical trials.

In our previous study, we had found that patients with T2DM and an increased baseline 10-year ASCVD risk may increase the CVD events in the future. In the present population-based prospective cohort study, we explored the incidence of CVD caused by various HbA1c categories among individuals with T2DM and first investigated this association stratified by the 10-year ASCVD risk.

RESEARCH DESIGN AND METHODS

Study population
The participants in this study were from the Chengqiao Town, Chongming District of Shanghai, China. Of 45,876 residents aged 40–70 years in the whole Chengqiao town, we randomly sampled 10,060 subjects to conduct our study using a stratified cluster sampling method. All eligible individuals within each of the selected community/street were sampled. Informed consent was obtained from all participants.

At baseline in 2011, a total of 10,060 subjects were recruited, among which 9930 had full information. The questionnaire and inquiry method used in this study were adopted from the Risk Evaluation of cAncers in Chinese diabeTic Individuals: A lONgitudinal (REACTION) study. We used 75 g oral glucose tolerance test (OGTT) to assess 2-hour glucose for those without known T2DM and used 100 g steamed bread that contained approximately similar carbohydrates for those with self-reported T2DM. Of the 9930 participants, 2484 had T2DM. At the end of 3.25 years of follow-up, 581 subjects with T2DM did not attend the study, and the rest 1903 patients with T2DM were followed up. After excluding 23 participants with previous CVD history, 1880 patients with T2DM were analyzed in this study (figure 1). Among the 1880 patients with T2DM, 61% of them are newly diagnosed.

Study end points
Cardiovascular events were documented as having cardiovascular death, coronary heart disease and cerebrovascular disease. Coronary heart disease was further defined as non-fatal myocardial infarction and coronary revascularization. Cerebrovascular disease includes cerebral hemorrhage and cerebral infarction from any cause. Information on cardiovascular deaths was obtained from the official death certificates of Chongming district.

Blood glucose and HbA1c measurement
Plasma glucose was measured during a 75 g OGTT, and T2DM was defined by a fasting plasma glucose level ≥7.0 mmol/L and/or a 2-hour postchallenge glucose level ≥11.1 mmol/L, a previous physician diagnosis of T2DM or use of antidiabetic medication at baseline. Plasma glucose and HbA1c were measured using the same methods as described before.

Other variables of interest
Triglycerides (TG), total serum cholesterol, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol were measured on an automatic analyzer (Hitachi 7080; Japan). Fasting insulin was determined by RIA (Linco Research, USA). Anthropometric measurements were conducted by 20 well-trained nurses or postgraduates. Medical history, smoking and drinking information were gathered by a questionnaire.

We adopted the equations developed by Yang et al to calculate the ASCVD risk score, which evolved from The Framingham Heart Study, but is more suitable for Chinese people. For the group with ASCVD risk score ≥10%, the mean and range of baseline 10-year ASCVD risk was 13.4% (11.7%–17.1%) in this study; we defined the group as moderate ASCVD risk group. The baseline 10-year ASCVD risk score <10% group was basic ASCVD risk group.

Statistical analysis
For database management and statistical analysis, we used SAS V.9.2 software. Data were presented as means±SD.
median (IQR) or number (%). One-way analysis of variance was used to compare the differences between groups at baseline. The log-rank test was used to compare the cumulative incidence of CVD between groups, with the Kaplan-Meier survival function to show the time to events. Unadjusted and adjusted HRs for cardiovascular events according to different HbA1c levels were estimated using Cox proportional hazards models. P values <0.05 were considered to be statistically significant.

RESULTS
Baseline characteristics
The cohort information was detailed in figure 1. The baseline characteristics of 1880 patients with T2DM are shown in table 1 according to different HbA1c levels. Participants with HbA1c of 7.0%–8.0% group were found to be more likely to have greater age and TG levels but lower HDL-C levels than that in the HbA1c≤6.5% group. Moreover, we compared the baseline characteristics in participants with T2DM who attended the follow-up study with those who did not and found no significant difference in glucose levels, blood lipid profile, systolic blood pressure and diastolic blood pressure between the two groups.

These patients with diabetes in our cohort had two special characteristics: 1) all patients were from a population-based cohort, 61% of these are newly diagnosed patients with diabetes and 2) the baseline 10-year ASCVD risk ranged from basic to moderate, there was no patient at higher ASCVD risk (baseline 10-year ASCVD risk >40%).

HbA1c category and CVD
During the follow-up, 100 patients with T2DM (5.3%) experienced a first CVD event, and the corresponding incidence of CVD per 1000 person-years for the HbA1c≤6.5%, 6.6%–7%, 7.0%–8.0% and >8% groups were 12.5, 21.8, 22.9 and 28.9, respectively. Kaplan-Meier survival curve for CVD events according to different HbA1c levels is shown in online supplementary figure 1.

Table 2 displays the HRs and 95% CIs for cardiovascular events by different HbA1c categories. Taken HbA1c≤6.5% as the reference, the HR for cardiovascular events was not significantly different in HbA1c 6.6%–6.9% group. A baseline HbA1c 7.0%–8.0% had a 1.84 times higher risk of developing CVD in the crude model. However, HbA1c 7.0%–8.0% did not significantly elevate the CVD risk when compared with the reference group after adjusting for age, sex and other factors, with HR of 1.72% and 95% CI 0.98 to 3.04. HbA1c>8.0% was significantly associated with development of CVD both in the crude model (HR 2.31; 95% CI 1.12 to 4.90) and in the adjusted model (HR 2.34; 95% CI 1.12 to 4.90).

HbA1c categories combined with baseline 10-year ASCVD risk and CVD
Table 3 showed the HRs and 95% CIs for cardiovascular events according to different HbA1c categories combined with baseline 10-year ASCVD risk. The participants were divided into four groups according to different HbA1c levels (≤6.5%, 6.6%–6.9%, 7.0%–8.0% or >8%) and further divided into eight groups according to both HbA1c levels and the baseline 10-year ASCVD risk score.

Taken HbA1c below 6.5% and basic baseline ASCVD risk group as the reference, HbA1c>8% was significantly associated with a higher CVD risk in the general patients with T2DM, and the HR was 2.11 (95% CI 1.11 to 4.02) for basic ASCVD risk group, and 3.34 (95% CI 1.60 to 6.97) for moderate ASCVD risk group, respectively. However, the HbA1c 7.0%–8.0% group was significantly associated with a higher CVD risk in patients with moderate ASCVD risk group (HR 2.48; 95% CI 1.15 to 5.32; p=0.02), but not in those with basic ASCVD risk group. The HbA1c 6.6%–6.9% group was not significantly associated with a higher CVD risk in patients with moderate ASCVD risk group.

The combined effects of various HbA1c categories and ASCVD risk stratification on the incidence of CVD are shown in figure 2. Rates per 1000 person-years were calculated in these eight groups.

DISCUSSION
Our study investigated the CVD risk caused by HbA1c 7.0%–8.0% in a Chinese population-based cohort and found to the best of our knowledge for the first time that HbA1c 7.0%–8.0% may result in a significantly higher CVD risk in Chinese patients with T2DM with moderate baseline ASCVD risk.

There is conflicting evidence regarding appropriate HbA1c targets for reducing CVD events in patients with T2DM. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial and Veterans Affairs Diabetes Trial (VADT) did not observe significant difference in cardiovascular outcomes between intensive and standard treatment groups. However, in two separate UK Prospective Diabetes Study (UKPDS) 33 and UKPDS 34 trials, there were more benefits attained from intensive treatment compared with conventional therapy. Evidence from the above different trials has not consistently shown beneficial effects of HbA1c targets between 7.0% and 8.0% on reducing macrovascular events and death. Baseline ASCVD risk might be an important confounder and an explanation for conflicting results in patients with T2DM.

The accurate assessment of individual risk can be of great value to guiding and facilitating the prevention of ASCVD. As early as in 1976, the Framingham Heart Study identified several risk factors and developed the first coronary heart disease risk equations. Since then, several tools for CVD risk evaluation have been published and have guided public health and clinical practice in different populations. However, these equations were all derived from Western samples, which limited their applicability to other populations.
## Table 1  Baseline characteristics of subjects with different HbA1c levels

| Characteristics | All | HbA1c ≤6.5% | HbA1c 6.6%–6.9% | HbA1c 7.0%–8.0% | HbA1c >8.0% | P value |
|-----------------|-----|-------------|-----------------|-----------------|-------------|---------|
| N               | 1880| 961         | 271             | 346             | 302         |         |
| Age (years)     | 59.1±6.9 | 58.7±7.0 | 58.8±6.6 | 60.3±6.5 | 59.0±6.9 | 0.004   |
| Male, n (%)     | 739 (39.3) | 378 (39.3) | 101 (37.3) | 134 (38.7) | 126 (41.7) | 0.74    |
| BMI (kg/m²)     | 25.5±3.5 | 25.4±3.5 | 26.1±4.2 | 25.7±3.1 | 25.2±3.3 | 0.014   |
| Waist-to-hip ratio | 0.90±0.06 | 0.90±0.06 | 0.91±0.08 | 0.91±0.06 | 0.91±0.06 | <0.0001 |
| SBP (mm Hg)     | 137.9±18.1 | 138.0±18.5 | 137.2±15.5 | 138.6±18.5 | 137.5±18.3 | 0.76    |
| DBP (mm Hg)     | 82.0±9.7 | 82.4±9.9 | 81.5±7.9 | 81.8±9.5 | 81.6±10.7 | 0.39    |
| HbA1c           | 7.0±1.5 | 5.96±0.4 | 6.7±0.1 | 7.4±0.3 | 9.8±1.6 | <0.0001 |
| FPG (mmol/L)    | 8.1±2.5 | 6.9±1.0 | 7.6±1.0 | 8.5±1.4 | 12±3.5 | <0.0001 |
| 2hPG (mmol/L)   | 13.7±4.5 | 11.7±3.0 | 13.1±2.8 | 14.8±3.4 | 19.3±5.3 | <0.0001 |
| HDL-C (mmol/L)  | 1.2±0.3 | 1.25±0.34 | 1.17±0.30 | 1.16±0.27 | 1.16±0.27 | <0.0001 |
| LDL-C (mmol/L)  | 2.7±0.8 | 2.7±0.8 | 2.8±0.9 | 2.7±0.8 | 2.8±0.8 | 0.42    |
| TC (mmol/L)     | 4.8±1.1 | 4.94±1.1 | 4.8±1.0 | 4.9±1.1 | 4.9±1.1 | 0.89    |
| TG (mmol/L)     | 1.65 (1.15–2.46) | 1.58 (1.11–2.39) | 1.68 (1.13–2.48) | 1.73 (1.28–2.57) | 1.67 (1.13–2.52) | 0.04    |
| Insulin         | 7.87 (5.30–11.10) | 7.70 (5.20–11.10) | 8.09 (5.38–11.30) | 8.13 (5.52–11.50) | 6.95 (4.80–10.50) | 0.19    |
| Hypertension, n (%) | 1252 (66.6) | 631 (65.9) | 185 (68.3) | 240 (69.4) | 195 (64.8) | 0.68    |
| Antihypertension therapy, n (%) | 413 (22.0) | 211 (22.0) | 72 (26.6) | 83 (24.0) | 47 (15.6) | 0.009   |
| Smoking, n (%)  | 342 (18.2) | 163 (17.0) | 41 (15.1) | 64 (18.5) | 74 (24.5) | 0.01    |
| Drinking, n (%) | 425 (22.6) | 204 (21.2) | 64 (23.6) | 84 (24.3) | 73 (24.2) | 0.54    |
| ASCVD score ≥10%, n (%) | 527 (28.0) | 259 (27.0) | 70 (25.8) | 109 (31.5) | 89 (29.5) | 0.31    |
| Newly diagnosed DM, n (%) | 1151 (61.2) | 770 (80.1) | 155 (57.2) | 140 (40.5) | 86 (28.5) | <0.001  |
| Diabetes duration of previous DM (years) | 6.0 (2.0–9.0) | 4.0 (2.0–6.7) | 4.0 (2.0–7.0) | 5.0 (2.5–8.0) | 7.0 (4.0–11.0) | <0.001  |

Data are means±SD or number (%) or median (IQR).
ASCVD, atherosclerotic CVD; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; 2hPG, 2-hour postchallenge glucose; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total serum cholesterol; TG, triglycerides.
Table 2  Adjusted HRs and 95% CIs for cardiovascular events according to HbA1c categories in Chinese patients with T2DM without cardiovascular event history

| HbA1c categories | N/total | Cases/1000 | Crude HR (95% CI) | Adjusted HR (95% CI) |
|------------------|---------|------------|-------------------|----------------------|
|                  |         | P-Ys       |                   | Model 1              | Model 2              |
| HbA1c ≤6.5%      | 35/961  | 12.5       | 1                 | 1                    | 1                    |
| HbA1c 6.6%–6.9%  | 17/271  | 21.8       | 1.74 (0.98 to 3.11)| 1.76 (0.99 to 3.15)  | 1.77 (0.98 to 3.19)  |
| HbA1c 7.0%–8.0%  | 23/346  | 22.9       | 1.84* (1.09 to 3.11)| 1.69 (1.00 to 2.87)  | 1.72 (0.98 to 3.04)  |
| HbA1c >8.0%      | 25/302  | 28.9       | 2.31** (1.38 to 3.86)| 2.29** (1.37 to 3.83) | 2.34* (1.12 to 4.90) |

Model 1 adjusted for age and sex.
Model 2 further adjusted for age, sex, WHR, LDL-C, HDL-C, TC, FPG, 2hPG, hypertension history and current smoking.

*P<0.05, **p<0.01.

FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; 2hPG, 2-hour postchallenge glucose; LDL-C, low-density lipoprotein cholesterol; P-Ys, person-years; TC, total serum cholesterol; T2DM, type 2 diabetes mellitus; TG, triglycerides; WHR, waist-to-hip ratio.

conducted the China-PAR project to develop and validate the Chinese ASCVD risk equations in multiple contemporary Chinese cohorts. The risk prediction equations provided a valuable tool to quantify risk and to guide individualized primary care among Chinese populations. The current population-based prospective cohort enabled us to explore the incidence of CVD among individuals with different HbA1c categories among patients with T2DM. As expected, we found that HbA1c>8.0% groups were significantly associated with a higher CVD risk in the general patients with T2DM (HR 2.34, 95% CI 1.12 to 4.90). However, after adjusting for age, sex and other factors, the HbA1c 7.0%–8.0% group was not significantly associated with a higher CVD risk in the general patients with T2DM. Our results were in line with the work by Palta et al. They uncovered an important findings that an HbA1c>8.0% was associated with increased risk of all-cause and cause-specific mortality in older adults with diabetes from the National Health and Nutrition Examination Surveys.

Our study further extend on existing literature by combining ASCVD score evaluation for individualized glycemic targets and we put our emphasis on the question of whether the combination of HbA1C and ASCVD risk score is predictive of incident CVD events. In our study, the HbA1c 7.0%–8.0% group was significantly associated with a higher CVD risk in patients with moderate baseline ASCVD risk (2.48, 95% CI 1.15 to 5.32), but not in those with basic baseline ASCVD risk. We provided the first data on the occurrence of CVD among Chinese adults combined with HbA1c 7.0%–8.0% and an estimated 10-year ASCVD risk, which supports the use of baseline ASCVD risk assessment to determine future treatment decisions among patients with T2DM with basic to moderate risk.

Limitations included the follow-up duration of about 3.25 years with CVD information recorded; 3.25 years may be relatively short and future studies with continuous follow-up of these participants are warranted to evaluate long-term health implications. Because therapies varied within groups, the impact on the outcomes of changes in HbA1c throughout follow-up is not being reported at this time. Because all patients with diabetes were from a Chinese population-based cohort and 61% of them were newly diagnosed patients with T2DM, there was no patient at higher ASCVD risk (baseline 10-year ASCVD risk >40%). Future studies are needed to discuss the association among patients with T2DM with different characteristics.

COnClusIOn
This study confirms that HbA1c 7.0%–8.0% combined with moderate baseline ASCVD risk may result in higher CVD

Table 3  Adjusted HRs and 95% CIs for cardiovascular events according to HbA1c categories and ASCVD risk score

| HbA1c         | ASCVD score      | N/total | Cases/1000 | P-Ys | HR (95% CI) | P value |
|---------------|------------------|---------|------------|------|-------------|---------|
| HbA1c ≤6.5%   | Basic ASCVD risk | 24/702  | 11.7       | 1    | 1           | /       |
|               | Moderate ASCVD risk | 11/259 | 14.7       | 1.26 (0.62 to 2.57) | 0.53 |
| HbA1c 6.6%–6.9% | Basic ASCVD risk | 13/201  | 22.5       | 1.93 (0.98 to 3.78) | 0.06 |
|               | Moderate ASCVD risk | 4/70    | 19.7       | 1.69 (0.59 to 4.86) | 0.33 |
| HbA1c 7.0%–8.0% | Basic ASCVD risk | 14/237  | 20.2       | 1.74 (0.90 to 3.36) | 0.10 |
|               | Moderate ASCVD risk | 9/109   | 28.9       | 2.48* (1.15 to 5.32) | 0.02 |
| HbA1c >8.0%   | Basic ASCVD risk | 15/213  | 24.6       | 2.11* (1.11 to 4.02) | 0.02 |
|               | Moderate ASCVD risk | 10/89   | 38.9       | 3.34** (1.60 to 6.97) | 0.00 |

*P<0.05, **p<0.01.

ASCVD, atherosclerotic CVD; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; P-Ys, person-years.
Cardiovascular and Metabolic Risk

Figure 2 The effect of various HbA1c categories and ASCVD risk stratification combined on the prevalence of CVD among Chinese patients with T2DM. Rates per 1000 person-years were calculated in these eight groups. ASCVD, atherosclerotic CVD; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; T2DM, type 2 diabetes mellitus.

risk among Chinese patients with T2DM. It is reasonable for patients with T2DM with HbA1c 7.0%–8.0% to have individualized treatment. In order to prevent CVD morbidity and mortality, more active intervention including pharmacological treatment should be strengthened among subjects with HbA1c 7.0%–8.0% and moderate baseline ASCVD risk. As to subjects with HbA1c 7.0%–8.0% and basic baseline ASCVD risk, a regular monitoring of blood pressure, glycemia and blood lipid in case of possible concurrent disorders are recommended.

Author affiliations
1 Department of Endocrinology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
2 Department of Endocrinology, Chongming Branch, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
3 Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
4 State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrine and Metabolic Diseases, Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Acknowledgements The authors would like to thank all staff and volunteers who attended this study. The authors would also like to thank Yihui Tian for her careful proofreading.

Contributors JT and QS contributed to the conception or design of the work. HZ, LQ, YN, HG, SL, ZY, JT, C-SS and QS contributed to the acquisition, analysis or interpretation of data for the work. JT, HZ and C-SS drafted the manuscript. QS critically revised the manuscript. All gave final approval and agreed to be accountable for all aspects of work ensuring integrity and accuracy.

Funding This work was supported by Shanghai Science and Technology Commission Key Program (10411956600, 15411952200), Shanghai Pujiang Talents Plan (18P14107200), Research Project Funded by the Shanghai Municipal Health Bureau (20114301), National Natural Science Foundation of China (81670743, 81770418 and 81270935) and National Key R&D Program of China (2016YFC1300103, 2016YFC0901200, 2016YFC0901203 and 2016YFC0905001).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study protocol was approved by the institutional review board of Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Jingyan Tian http://orcid.org/0000-0002-0569-7615

REFERENCES
1 American Diabetes Association. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41:S86–104.
2 Syed IAA. Glycated haemoglobin; past, present, and future are we ready for the change. J Pak Med Assoc 2011;61:383–8.
3 Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c targets for glyemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guideline statement update from the American College of physicians. Ann Intern Med 2018;168:569–76.
4 Riddle MC, Gerstein HC, Holman RR, et al. A1C targets should be personalized to maximize benefits while limiting risks. Diabetes Care 2018;41:1121–4.
5 Bloomgarden Z, Einhorn D, Handelsman Y, et al. American College of physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia. J Diabetes 2018;10:618–20.
6 Williams B, Mancia G, Sipiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021–104.
7 Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ABC/ACP/AGS/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: a report of the American College of Cardiology/American heart association Task force on clinical practice guidelines. Hypertension 2018;71:1269–324.
8 Kats D, Sharrett AR, Ginsberg HN, et al. Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis risk in communities (ARIC) study. BMJ Open Diabetes Res Care 2017;5.
9 Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract 2017;23:479–97.
10 Tian J, Sheng C-S, Sun W, et al. Effects of high blood pressure on cardiovascular disease events among Chinese adults with different glucose metabolism. Diabetes Care 2018;41:1985–900.
11 Ning G, Reaction Study Group. Risk evaluation of Cancers in Chinese diaBeTic individuals: a IONgitudinal (reaction) study. J Diabetes 2012;4:172–3.
12 Qiu M, Shen W, Song X, et al. Effects of prediabetes mellitus alone or plus hyperpertension on subsequent occurrence of cardiovascular disease and diabetes mellitus: longitudinal study. Hypertension 2015;65:525–30.
13 Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:345–59.
14 Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population. Circulation 2016;134:1430–40.
15 D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 2008;117:743–53.
16 Gerstein HC, Miller ME, Genuith S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818–28.
17 Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72.
18 Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–39.
19 Anon. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet 1998;352:837–53.
20 Anon. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet 1998;352:854–65.
21 Ueki K, SASako T, Kato M, et al. Design of and rationale for the Japan diabetes optimal integrated treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-
label, randomized, parallel-group trial. *BMJ Open Diabetes Res Care* 2016;4:e000123.

22 Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham study. *Am J Cardiol* 1976;38:46–51.

23 Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;97:1837–47.

24 Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the score project. *Eur Heart J* 2003;24:987–1003.

25 Palta P, Huang ES, Kalyani RR, et al. Hemoglobin A1c and Mortality in Older Adults With and Without Diabetes: Results From the National Health and Nutrition Examination Surveys (1988-2011). *Diabetes Care* 2017;40:453–60.